Therapy Areas: Diabetes
APR Publishes Clinical Data Supporting Nexodyn AcidOxidizing Solution for Management of Chronic Wounds
21 May 2018 - - Balerna, Switzerland-based healthcare products developer Applied Pharma Research SA (APR) has published results of a clinical pilot study on the efficacy and tolerability of Nexodyn AcidOxidizing Solution in the April 2018 "Advances in skin and wound care," the company said.
Nexodyn AcidOxidizing Solution is a sprayable active cleanser with ancillary antimicrobial activity developed for acute and chronic wound management, and intended for use in the debridement, irrigation, cleansing, and moistening of acute and chronic wounds (e.g. diabetic foot ulcers, pressure ulcers, vascular ulcers), post-surgical wounds, burns, and other lesions.
The pilot study, conducted with a prospective, single-arm design, engaged 30 patients with critically colonized or locally infected chronic leg ulcers of any origin.
Nexodyn AcidOxidizing Solution was applied on each leg ulcer at every dress change for 35 days together with a nonadherent gauze and a multi-purpose absorbent dressing. By the end of the study period, treatment with Nexodyn AcidOxidizing Solution led to the full healing of 37% of the chronic wounds as well as to a significant decrease in wound size.
Additionally, wound-associated infections were eliminated, together with a reduction in pH values and local bioburden covering the wound, whilst no reinfection of any examined wounds was observed during the study.
Results suggest that, due to its synergic and distinctive physico-chemical properties, the cleanser could play a role in the management of chronic wounds as it effectively promotes wound rebooting by creating the ideal microenvironment to sustain the physiological healing process and favors an optimized lesion closure.
Data also confirm a favorable safety and tolerability profile, especially relevant in chronic wounds, with no adverse events reported over the study duration, high levels of pain relief and comfort at application, as well as wound-associated pain reduction.
APR develops science driven, patent protected healthcare products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis.
The company is currently focused on internally developed and financed proprietary products to be licensed to healthcare companies for their commercialization, and support to third party projects by offering added value R and D services under contract and fee for service arrangements.
Login
Username:

Password: